Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination.
Saved in:
| Title: | Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination. |
|---|---|
| Authors: | Kister, Ilya1 (AUTHOR) ilya.kister@nyulangone.org, Curtin, Ryan2 (AUTHOR), Piquet, Amanda L.3 (AUTHOR), Borko, Tyler3 (AUTHOR), Pei, Jinglan4 (AUTHOR), Banbury, Barbara L5 (AUTHOR), Bacon, Tamar E.1 (AUTHOR), Kim, Angie1 (AUTHOR), Tuen, Michael6 (AUTHOR), Velmurugu, Yogambigai2 (AUTHOR), Nyovanie, Samantha2 (AUTHOR), Selva, Sean3 (AUTHOR), Samanovic, Marie I.6 (AUTHOR), Mulligan, Mark J.6 (AUTHOR), Patskovsky, Yury2 (AUTHOR), Priest, Jessica4 (AUTHOR), Cabatingan, Mark4 (AUTHOR), Winger, Ryan C.4 (AUTHOR), Krogsgaard, Michelle2 (AUTHOR) michelle.krogsgaard@nyulangone.org, Silverman, Gregg J.7 (AUTHOR) gregg.silverman@nyulangone.org |
| Source: | Annals of Clinical & Translational Neurology. Jul2024, Vol. 11 Issue 7, p1750-1764. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
